Procept Biorobotics Q1 revenue beats estimates

PROCEPT BioRobotics

29/04/2026 21:20

Overview

Surgical robotics firm's Q1 revenue rose 20% yr/yr, beating analyst expectations

Q1 adjusted EBITDA loss beat analyst estimates

Company received FDA clearance for second-generation AI software for Aquablation therapy

Outlook

Procept Biorobotics expects 2026 revenue of $390 mln to $410 mln, up 27%-33% year-on-year

Company maintains 2026 U.S. procedure growth outlook of 39% to 48%

Procept Biorobotics continues to forecast 2026 gross margin of about 65%

Result Drivers

U.S. SYSTEM SALES AND PRICING - Q1 revenue growth was driven by strong U.S. system sales and improved pricing, according to CEO Larry Wood

PROCEDURE VOLUME - U.S. procedures rose 30% yr/yr, supporting higher handpiece and consumable sales

INTERNATIONAL GROWTH - International revenue increased 25% yr/yr, contributing to overall revenue growth

Company press release: ID:nGNX4t81X6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$83.13 mln
$80.51 mln (13 Analysts)
Q1 EPS
-$0.56
Q1 Net Income
-$31.64 mln
Q1 Adjusted EBITDA
Beat
-$18.12 mln
-$18.66 mln (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Procept Biorobotics Corp is $30.50, about 32.4% above its April 28 closing price of $23.03

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)